3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
5
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
8
Nivolumab
5
avelumab
4
Ipilimumab
4
Radiotherapy
2
Radiosurgery
2
ALT-803
2
tremelimumab
1
talimogene laherparepvec
1
sapanisertib
1
prednylidene
1
poly ICLC
1
lenvatinib
1
interferon gamma-1b
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
deltacortene
1
cemiplimab
1
cabozantinib
1
bempegaldesleukin
1
atezolizumab
1
Tacrolimus
1
Radiation Dose Hypofractionation
1
Radiation
1
Prednisone
1
Interferon-gamma
1
Interferon-beta
1
CTLA-4 Antigen
1
B7-H1 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Merkel Cell
×
bempegaldesleukin
×
Clear all
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts